These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10125706)

  • 21. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 23. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 24. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 25. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic equivalents in clinical practice.
    Benson MD
    Int J Fertil Womens Med; 2001; 46(2):89-94. PubMed ID: 11374660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis.
    Sullivan PW; Follin SL; Nichol MB
    Med Care; 2003 Dec; 41(12):1382-95. PubMed ID: 14668671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and effectiveness: an opportunity for clinical pharmacology.
    Lalonde RL; Willke RJ
    Clin Pharmacol Ther; 2011 Dec; 90(6):761-3. PubMed ID: 22089338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic drugs--safe, effective, and affordable.
    Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
    Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic drug product equivalence: current status.
    Meyer MC
    Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 35. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
    Docherty JP; Browne RA; Farmer M
    Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.
    Fendrick AM; Smith DG; Chernew ME; Shah SN
    Am J Manag Care; 2001 Sep; 7(9):861-7. PubMed ID: 11570020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Takings issues in the approval of generic biologics.
    Yoo JC
    Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
    [No Abstract]   [Full Text] [Related]  

  • 38. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 39. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for acquiring affordable medications for seniors.
    Morris KJ
    Nurs Clin North Am; 2005 Mar; 40(1):51-62, vi. PubMed ID: 15733946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.